Why Most Material Transfer Agreements Quietly Kill Downstream Commercialization
MTAs look like administrative paperwork, but buried clauses routinely strip universities and startups of the IP rights they need to commercialize research.
A. Kovacs Topic
university spinouts
9 posts tagged university spinouts from Commercializing Science.
A. Kovacs More on university spinouts
Why Most IP Assignment Clauses in Research Agreements Sabotage the Deal Later
Vague IP assignment language in sponsored research agreements creates ownership disputes that kill commercialization deals years after the science is done.
A. KovacsWhy Exclusive Licenses Destroy More Value Than They Create
Exclusive licenses feel like wins for everyone at signing. Here's why they quietly kill commercialization, and what to structure instead.
A. KovacsWhy Option Agreements Are the Most Misused Tool in Technology Transfer
Option agreements should de-risk early licensing deals, but most TTOs use them wrong. Here's what's broken and how to fix it.
A. KovacsWhy Most Invention Disclosure Forms Kill Commercialization Before It Starts
Invention disclosure forms are often the first step in tech transfer, and one of the most damaging. Here's what needs to change.
A. KovacsWhy Most Technology Readiness Level Assessments Lie to Everyone Involved
TRL scores feel objective but are routinely gamed or misread. Here's what's really happening and how to use them honestly.
A. KovacsWhy Proof-of-Concept Funding Is the Leverage Point Nobody Talks About
Proof-of-concept funding is the missing bridge between lab discovery and licensable technology, here's why most institutions underinvest in it.
A. KovacsWhy Most Licensing Term Sheets Die in Negotiation (And How to Rescue Them)
Most university licensing deals collapse not because of bad science or bad intent, but because of preventable negotiation failures. Here's what actually goes wrong.
A. KovacsWhy Corporate Venture Arms Keep Missing the Best University Deals
Corporate VCs systematically lose out on promising university spinouts due to misaligned incentives and poor deal sourcing strategies.
A. Kovacs Browse more topics